Moreover, our results suggest that there is a plausible threshold of LDHC expression to elicit an anti-tumor immunity since we observed attenuated T cell responses against the HLA-A*0201 breast cancer cell line following LDHC silencing. The gene discussed is HLA-A; the disease is breast carcinoma.